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Changsong Wang1*, Yanping Chen1, Chunfang Gao1, Jian Yin1 and Hong Li2Abstract
Objective: To study the clinico-pathological characteristics of Langerhans cell sarcoma (LCS) which involving
epidermis.
Methods: A case of primary multifocal LCS was analyzed in histopathology and immunophenotype.
Results: A 41-year-old man with multifocal cutaneous LCS involving the inguina and waist was reported. Clinical
and pathology data were available. Neoplastic cells with markedly malignant cytological features were observed.
Tumor cells exhibited irregular shape with abundant and eosinophilic red staining cytoplasm; large,
irregular-shaped, showing lobulated or dented nucleus and some cells with a longitudinal nuclear groove and
prominent nucleoli. The tumor cells expressed CD1a, Langerin (CD207), S-100 protein, CD68 and vimentin, and did
not express pan-T or B cell markers and epithelial markers. The patient died less than 1 year after diagnosis due to
local recurrence and metastasis to the lung, despite the administration of local radiation and chemotherapy.
Conclusions: LCS is a tumor with markedly malignant cytological features that originates from Langerhans cells.
Primary multifocal neoplasms involving epidermis is even rare. Accurate diagnosis is based on the histopathological
and immunohistochemical of the tumor cells.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1182345104754765.
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The Langerhans cell tumors were classified into Langer-
hans cell histiocytosis (LCH) and Langerhans cell sar-
coma (LCS) by the World Health Organization (WHO)
in 2001. LCS is a rare dendritic cell tumor, and the
WHO defined it as having typical features of malignant
cytology as a high-grade variant of LCH [1]. The diagno-
sis of LCS is difficult, and it is necessary to differentiate
it from many other tumors, such as metastatic cancer,
malignant melanoma, anaplastic large cell lymphoma,
myeloid sarcoma, malignant fibrous histiocytoma and
LCH. In addition, the tumors of LCH and LCS both
arise from dendritic cells and have the same histological
features, immunophenotype, and Birbeck granules in the
cytoplasm. Therefore, differentiating between LCS and* Correspondence: wangtmmu@yahoo.com.cn
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reproduction in any medium, provided the orLCH is difficult. LCS occure at any age and involve
many organs or tissues, such as bone, lung, lymph
nodes, liver and soft tissues. LCS involved epidermis to
form multiple focus was still rare, in the present report,
we reported such a case of LCS.Case presentation
Clinical summary
A 41-year-old man with a slowly growing soft tissue
mass (which was painful when manual pressure was ap-
plied), which developed over a period of 6 months, over
the anterior iliac spine was reported. The wound healed
poorly after the operation and recurred as a cord-like
tissue from the wound to the left groin. This cord-like
tissue disappeared upon administration of antibiotic
therapy. Then, a small mass with no pain emerged at his
left groin, and treatment with antibiotics had no effect.
The mass gradually become large and solid. Another
mass emerged at the right groin during the first month.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Hematoxylin-eosin staining of LCS (200×).
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http://www.diagnosticpathology.org/content/7/1/99Physical examination indicated that the masses were
located at the bilateral groins and at the left waist with a
sharp border. The masses at the right groin, left groin
and left waist had sizes of 3 cm× 6 cm, 15 cm× 8 cm
and 10 cm× 8 cm, respectively. There were no swollen
lymph nodes at the surface of the skin.
Upon operating, the mass was determined to be
located subcutaneously and had a clear border.
Pathological findings
The specimens that were obtained consisted of a few
broken pieces and a little subcutaneous tissue, measuring
13 cm× 10 cm× 4 cm. The cut surface was gray-white,
soft and had a pseudo-membrane. Microscopically, the
majority of the larger tumor cells were located diffusely
under the dermis and subcutaneous tissue (Figure 1).
The cell morphology varied as follows: irregular shape
with abundant and eosinophilic red staining cytoplasm;
large, irregular-shaped, showing lobulated or dented nu-
cleus and some cells with a longitudinal nuclear groove
and prominent nucleoli; and a large number of multinuc-
lear giant cells with a few or several dozen nuclei. These
cells had significantly malignant cytological features. A
high mitotic rate (more than 30 mitoses per 10 high
power fields) was observed. The tumor cells were sur-
rounded by a small amount of fibrous tissue. A large
number of neutrophils, giant cells, a small number of
plasma cells, eosinophils and lymphocytes in phagocytic
cells were observed, interspersed with the tumor cells
(Figure 2).
Immunohistochemical staining and results
The formalin-fixed paraffin-embedded tumor samples
were sliced in 3-μm-thick sections, and the sections
were prepared for hematoxylin and eosin staining and
for immunohistochemical detection.Figure 1 Hematoxylin-eosin staining of LCS (100×).The sections were pressure cooked for 15 min in
10 mM citrate buffer (pH 6.0) for antigen retrieval after
being dewaxed with xylene and rehydrated through a
graded series of ethanol. The sections were then incu-
bated in phosphate-buffered saline containing horse
serum albumin, and the primary antibodies were added
for the reaction. The reaction with the primary anti-
bodies was performed at 4°C overnight, then the second
antibody was added and incubated at 37°C for 30 min.
Finally, the sections were treated with 3% H2O2 to re-
duce endogenous peroxidase activity, and the reaction
was visualized with DAB.
The LCS tumor cells expressed Langerin (Monoclonal
mouse IgG (12D6), 1:200, Abcam. Figure 3), S-100 protein
(Monoclonal mouse IgG (8B10), Abcam, 1:800, Figure 4),
CD1a (Monoclonal mouse IgG (7A7), Abcam, 1:200,
Figure 5), vimentin and CD68 (Monoclonal mouse IgG
(3 F103), 1:50, Santa cruz) in the majority of cells. Lyso-
zyme was weakly positive, and no tumor cells expressed
CD20, CD3, CD30, AE1/AE3, LCA, CD23, CD35, CD56,Figure 3 LCS tumor cells expressed Langerin (400×).
Figure 4 LCS tumor cells expressed S-100 protein (400×).
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eration index ranged from 70%-90%.Treatment and follow-up
After operation, a combination treatment protocol of cyclo-
phosphamide, oncovin and prednisone (COP) was admini-
strated. Six courses of cyclophosphamide (800 mg/m2, 1d),
oncovin (2 mg/m2, 1d) and prednisone (60 mg/m2, 1-5d)
were applied. At the same time, local radiation therapy with
medical linear accerlerator (DT3600 cGy, 18 times) was
carried out. But the result was negative, as the mass re-
curred at the right hip 2 months later. Another treatment
protocols CHOP (cyclophosphamide, 750 mg/m2, 1d;
doxorubicin, 50 mg/m2, 1d; oncovin, 1.4 mg/m2, 1d and
prednisone, 100 mg/m2, 1-5d) was administrated with 6
courses. The patient died of metastasis in multiple organs
(liver and lung) less than 1 year after being diagnosed with
the disease.Figure 5 LCS tumor cells expressed CD1a (400×).Conclusions
The first case of LCS was reported by Wood, who indi-
cated that these tumor cells were antigen-presenting
cells or dendritic cells that arose from hematopoietic or
mesenchymal stem cells. The tumors of dendritic cells
include Langerhans cell histiocytosis, Langerhans cell
sarcoma, finger-like dendritic cell sarcoma/tumor, fol-
licular dendritic cell sarcoma/tumor, and the declassified
dendritic cell sarcoma, according to the 2008 WHO
tumor classification [1]. LCS was defined as a tumor of
Langerhans cell hyperplasia with markedly malignant
cytological features. It can be considered to be a high-
level variant of LCH at the beginning stages of LCS or
as having progressed from LCH. The published literature
has indicated that the majority of LCS cases are primary
tumors and that only one reported case was a tumor
that progressed from LCH [2].
The ages of reported patients of LCS ranged from 2 to
81 years, with a broad age distribution in adults and only
4 cases were younger than 18 years of age [3-5]. The
ages of the five cases that were reported in the Chinese
literature were 2, 18, 22, 41, 57 years (with a median age
of 28 years). This age range is significantly younger than
that of the cases reported in the English literature. Eight-
een cases involved an organ (6 cases from the skin, 6
cases from the lymph nodes, 1 case from the lungs, 1
case from the mediastinum and 4 cases from bone and
bone marrow) [6,7]. The majority of the cases of LCS
involved skin, lymph node, bone and bone marrow, and
most cases involved only a single organ. Bohn, et al.
summarized 20 cases of LCS over 1992–2007 and found
that most cases of LCS involved lymph node and skin
and that only a small number of cases involved the lung,
liver, spleen and bone marrow [8]. Lee, et al. summar-
ized 19 cases of LCS from 1973–2006 and concluded
that most of the patients had lymph node, spleen, liver,
bone marrow, thymus, lung and kidney involvement, in
addition to skin [2]. All of these reported literatures
showed that one primary focus.
The diagnostic factors of LCS includes: typical histo-
logical features of tumor cells with characteristics of
Langerhans cells; typical immunophenotype, such as,
Langerin, CD1a, S-100; and ultra-structure characteris-
tics, Birbeck granules within the cytoplasm. Occasion-
ally, tumor cells with poorly differentiated or atypical
morphology may lose the characteristics of ultra-
structure or immunophenotype. Ben-Ezra J reported
that only 3 cases presented Birbeck granules in the
cytoplasm, among 9 cases of LCS [9]. Therefore, there
are typical histological and immunophenotypic charac-
teristics that can also be diagnosed as LCS. In our
case, ultra-structural analysis did not indicate Birbeck
granules in the cytoplasm of the neoplastic cells in
this case.
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combination of radiotherapy with chemotherapy. Some
patients are treated with surgery and local radiotherapy,
but the results are less positive. LCS has been reported to
be completely restored after using MAID [10] or a modi-
fied ESHAP regimen (etoposide, carboplatin, cytarabine,
and methylprednisolone) [11]. According to the litera-
ture, there is no relationship between the survival time,
the number of organs involved, age and the treatment
protocol. About 50% of patients have died within 1.5 years
after diagnosis, so we conclude that LCS is a highly ma-
lignant tumor with a low survival rate and a poor prog-
nosis. LCS may progress to leukemia [12], at which
point, the immunophenotype of the tumor cells changes;
it may be a LCS clinical manifestation to predict the pro-
gression. Tumor cells have also been shown to present a
greater capacity for migration [13], and CD56 has
marked prognostic significance and may prove useful as
a clinically-relevant biological marker of Langerhans cell
neoplasms [14]. However, no expression of CD56 was
observed in the present case. A follow-up may have also
been an effective means to identify the LCS in another
report [7]. As for this case, chemotherapy and local radi-
ation therapy were administrated after the operation. But
the result was negative, as the mass recurred at the right
hip 2 months later. One month after that, a chest X-ray
showed a mass (3.9 cm×2.9 cm) at the right lower lung.
At the same time, the neoplasm recurred at the operation
site. The treatment regime was so ineffective that the pa-
tient died of metastasis in multiple organs less than 1 year
after being diagnosed with the disease.
In summary, we studied the clinical manifestation,
immunophenotype and treatment course of a case of
LCS with multiple primary foci. Due to its low incidence,
it is vital to be able to recognize this highly malignant
neoplasm and to differentiate it from other neoplasms.
Accurate diagnosis is based on the morphologic features
of the tumor cells and on the immunophenotype of the
tumor cells.Consent
Written informed consent was obtained from the wife of
the patient for publication of this Case Report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
CSW was responsible for literature search and manuscript preparation. CFG
and YPC participated in the discussion for histological diagnosis and
manuscript preparation. JY collected the clinical data and postoperative
clinical follow-up of the patient. CSW and HLi participated in the microscopic
analyses. All authors read and approved the final manuscript.Acknowledgements
We thank Professor Fusheng Liu for his assistance. This work was supported
by The National Natural Science Foundation of China (NSFC No. 30672299).
Author details
1Department of Pathology, 150th Hospital of PLA, Luoyang, China.
2Department of Otorhinolaryngology and Head-Neck Surgery, Xinqiao
Hospital, Third Military Medical University, Chongqing, China.
Received: 26 June 2012 Accepted: 6 August 2012
Published: 14 August 2012
References
1. Jaffe E, Harris N, Stein H, et al: Tumors derived from Langerhans cells. In
World Health Organization classification of tumours: Pathology and genetics,
tumours of haematopoietic and lymphoid tissues. Edited by Barnes L, Eveson
JW, Reichart P, Sidransky D. Lyon: IARC Press; 2008:278–289.
2. Lee JS, Ko GH, Kim HC, et al: Langerhans cell sarcoma arising from
Langerhans cell histiocytosis: a case report. J Korean Med Sci 2006,
21:577–580.
3. Shi-Yuan He X-LZ: 2 cases of Langerhans cell sarcoma misdiagnosed.
J Guangxi Trad Chin Med University 2000, 17:93–95.
4. Jing Chen J-YT, Ci PAN, et al: Langerhans cell sarcoma: the clinical
features and diagnosis. J China Pediatr Blood Cancer 2007, 12:213–214.
5. Lian YL, He HY, Liao SL, et al: Langerhans cell sarcoma of talus: report of a
case. Zhonghua Bing Li Xue Za Zhi 2006, 35:697–698.
6. Langfort R, Radzikowska E, Czarnowska E, et al: Langerhans cell sarcoma
with pulmonary manifestation, mediastinum involvement and
bronchoesophageal fistula. A rare location and difficulties in
histopathological diagnosis. Pneumonol Alergol Pol 2009, 77:327–334.
7. Gang Zhao ML, Zhi-Yong W, Qiang L, et al: Langerhans Cell Sarcoma
Involving Gallbladder and Peritoneal Lymph Nodes: A Case Report.
Int J Surg Pathol 2009, 17:347–353.
8. Bohn OL, Ruiz-Arguelles G, Navarro L, et al: Cutaneous Langerhans cell
sarcoma: a case report and review of the literature. Int J Hematol 2007,
85:116–120.
9. Ben-Ezra J, Bailey A, Azumi N, et al: Malignant histiocytosis X. A distinct
clinicopathologic entity. Cancer 1991, 68:1050–1060.
10. Uchida K, Kobayashi S, Inukai T, et al: Langerhans cell sarcoma emanating
from the upper arm skin: successful treatment by MAID regimen.
J Orthop Sci 2008, 13:89–93.
11. Yoshimi A, Kumano K, Motokura T, et al: ESHAP therapy effective in a
patient with Langerhans cell sarcoma. Int J Hematol 2008, 87:532–537.
12. Sumida K, Yoshidomi Y, Koga H, et al: Leukemic transformation of
Langerhans cell sarcoma. Int J Hematol 2008, 87:527–531.
13. Ferringer T, Banks PM, Metcalf JS: Langerhans cell sarcoma.
Am J Dermatopathol 2006, 28:36–39.
14. Kawase T, Hamazaki M, Ogura M, et al: CD56/NCAM-positive Langerhans
cell sarcoma: a clinicopathologic study of 4 cases. Int J Hematol 2005,
81:323–329.
doi:10.1186/1746-1596-7-99
Cite this article as: Wang et al.: Multifocal Langerhans cell sarcoma
involving epidermis: a case report and review. Diagnostic Pathology 2012
7:99.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
